Utilization of percutaneous left atrial appendage closure in patients with atrial fibrillation: an update on patient outcomes

References

• Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA. 2001;285(18):2370–2375.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the heart rhythm society. Circulation. 2014;130(23):e199–267.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–2962.
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics- 2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56–e528.
   PubMed Web of Science ®Google Scholar
• Marinigh R, Lip GY, Fiotti N, et al. Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis. J Am Coll Cardiol. 2010;56(11):827–837.
   PubMed Web of Science ®Google Scholar
• McGrath ER, Kapral MK, Fang J, et al. Association of atrial fibrillation with mortality and disability after ischemic stroke. Neurology. 2013;81(9):825–832.
   PubMed Web of Science ®Google Scholar
• Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137(2):263–272.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125–e151.
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–867.
   PubMed Web of Science ®Google Scholar
• Mazurek M, Shantsila E, Lane DA, et al. Secondary versus primary stroke prevention in atrial fibrillation: insights from the Darlington Atrial Fibrillation Registry. Stroke. 2017;48(8):2198–2205.
   PubMed Web of Science ®Google Scholar
• Yao X, Abraham NS, Alexander GC, et al. Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. J Am Heart Assoc. 2016;5(2):e003074.
   PubMed Web of Science ®Google Scholar
• Yao X, Shah ND, Sangaralingham LR, et al. Reply: NOAC dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol. 2017;70(21):2734–2735.
   PubMed Web of Science ®Google Scholar
• Hylek EM, D’Antonio J, Evans-Molina C, et al. Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke. 2006;37(4):1075–1080.
   PubMed Web of Science ®Google Scholar
• Kuno T, Takagi H, Ando T, et al. Oral anticoagulation for patients with atrial fibrillation on long-term hemodialysis. J Am Coll Cardiol. 2020;75(3):273–285.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–2104.
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962.
   PubMed Web of Science ®Google Scholar
• Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–1100.
   PubMed Web of Science ®Google Scholar
• Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996;61(2):755–759.
   PubMed Web of Science ®Google Scholar
• Stoddard MF, Dawkins PR, Prince CR, et al. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. J Am Coll Cardiol. 1995;25(2):452–459.
   PubMed Web of Science ®Google Scholar
• Beigel R, Wunderlich NC, Ho SY, et al. The left atrial appendage: anatomy, function, and noninvasive evaluation. JACC Cardiovasc Imaging. 2014;7(12):1251–1265.
   PubMed Web of Science ®Google Scholar
• Di Biase L, Santangeli P, Anselmino M, et al. Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation? Results from a multicenter study. J Am Coll Cardiol. 2012;60(6):531–538.
   PubMed Web of Science ®Google Scholar
• Madden JL. Resection of the left auricular appendix; a prophylaxis for recurrent arterial emboli. J Am Med Assoc. 1949;140(9):769–772.
   PubMed Web of Science ®Google Scholar
• Johnson WD, Ganjoo AK, Stone CD, et al. The left atrial appendage: our most lethal human attachment! Surgical implications. Eur J Cardiothorac Surg. 2000;17(6):718–722.
   PubMed Web of Science ®Google Scholar
• Ibrahim AM, Tandan N, Koester C, et al. Meta-analysis evaluating outcomes of surgical left atrial appendage occlusion during cardiac surgery. Am J Cardiol. 2019;124(8):1218–1225.
   PubMed Web of Science ®Google Scholar
• Park-Hansen J, Holme SJV, Irmukhamedov A, et al. Adding left atrial appendage closure to open heart surgery provides protection from ischemic brain injury six years after surgery independently of atrial fibrillation history: the LAACS randomized study. J Cardiothorac Surg. 2018;13(1):53.
   PubMedGoogle Scholar
• Badhwar V, Rankin JS, Damiano RJ, et al. The Society of Thoracic Surgeons 2017 clinical practice guidelines for the surgical treatment of atrial fibrillation. Ann Thorac Surg. 2017;103(1):329–341.
   PubMed Web of Science ®Google Scholar
• Katz ES, Tsiamtsiouris T, Applebaum RM, et al. Surgical left atrial appendage ligation is frequently incomplete: a transesophageal echocardiograhic study. J Am Coll Cardiol. 2000;36(2):468–471.
   PubMed Web of Science ®Google Scholar
• García-Fernández MA, Pérez-David E, Quiles J, et al. Role of left atrial appendage obliteration in stroke reduction in patients with mitral valve prosthesis: a transesophageal echocardiographic study. J Am Coll Cardiol. 2003;42(7):1253–1258.
   PubMed Web of Science ®Google Scholar
• Kanderian AS, Gillinov AM, Pettersson GB, et al. Success of surgical left atrial appendage closure: assessment by transesophageal echocardiography. J Am Coll Cardiol. 2008;52(11):924–929.
   PubMedGoogle Scholar
• Glikson M, Wolff R, Hindricks G, et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update. EuroIntervention. 2020;15(13):1133–1180.
   PubMed Web of Science ®Google Scholar
• Sievert H, Lesh MD, Trepels T, et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation. 2002;105(16):1887–1889.
   PubMed Web of Science ®Google Scholar
• Lakkireddy D, Afzal MR, Lee RJ, et al. Short and long-term outcomes of percutaneous left atrial appendage suture ligation: results from a US multicenter evaluation. Heart Rhythm. 2016;13(5):1030–1036.
   PubMed Web of Science ®Google Scholar
• Akella K, Murtaza G, Turagam M, et al. Evaluating the role of transesophageal echocardiography (TEE) or intracardiac echocardiography (ICE) in left atrial appendage occlusion: a meta-analysis. J Interv Card Electrophysiol. 2020. DOI:10.1007/s10840-019-00677-x.
   Web of Science ®Google Scholar
• Kleinecke C, Fuerholz M, Buffle E, et al. Amplatzer left atrial appendage closure: access via transseptal puncture versus patent foramen ovale or atrial septal defect. EuroIntervention. 2019. DOI:10.1007/s10840-019-00635-7.
   Web of Science ®Google Scholar
• Meier B, Blaauw Y, Khattab AA, et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. EuroIntervention. 2015;10(9):1109–1125.
   PubMed Web of Science ®Google Scholar
• Freeman JV, Varosy P, Price MJ, et al. The NCDR left atrial appendage occlusion registry. J Am Coll Cardiol. 2020;75(13):1503–1518.
   PubMed Web of Science ®Google Scholar
• Landmesser U, Schmidt B, Nielsen-Kudsk JE, et al. Left atrial appendage occlusion with the AMPLATZER Amulet device: periprocedural and early clinical/echocardiographic data from a global prospective observational study. EuroIntervention. 2017;13(7):867–876.
   PubMed Web of Science ®Google Scholar
• Brachmann J, Lewalter T, Akin I, et al. Interventional occlusion of left atrial appendage in patients with atrial fibrillation. acute and long-term outcome of occluder implantation in the LAARGE registry. J Interv Card Electrophysiol. 2019. DOI:10.1007/s10840-019-00635-7.
   Web of Science ®Google Scholar
• Berti S, Santoro G, Palmieri C, et al. Tools and techniques clinical: transcatheter closure of left atrial appendage using the Amplatzer cardiac plug. EuroIntervention. 2013;9(4):524–526.
   PubMed Web of Science ®Google Scholar
• Afzal MR, Ellis CR, Gabriels J, et al. Percutaneous approaches for retrieval of an embolized or malpositioned left atrial appendage closure device: A multicenter experience. Heart Rhythm. 2020;S1547-5271(20):30356–30358.
   Google Scholar
• Hornung M, Gafoor S, Id D, et al. Catheter-based closure of residual leaks after percutaneous occlusion of the left atrial appendage. Catheter Cardiovasc Interv. 2016;87(7):1324–1330.
   PubMed Web of Science ®Google Scholar
• Pracon R, Bangalore S, Dzielinska Z, et al. Device thrombosis after percutaneous left atrial appendage occlusion is related to patient and procedural characteristics but not to duration of postimplantation dual antiplatelet therapy. Circ Cardiovasc Interv. 2018;11(3):e005997.
   PubMed Web of Science ®Google Scholar
• Meier B. What lies beneath left atrial appendage ccclusion: know your enemy. Circ Cardiovasc Interv. 2018;11(3):e006360.
   PubMed Web of Science ®Google Scholar
• Saw J, Tzikas A, Shakir S, et al. Incidence and clinical impact of device-associated thrombus and peri-device leak following left atrial appendage closure with the Amplatzer Cardiac Plug. JACC Cardiovasc Interv. 2017;10(4):391–399.
   PubMed Web of Science ®Google Scholar
• Saw J, Fahmy P, DeJong P, et al. Cardiac CT angiography for device surveillance after endovascular left atrial appendage closure. Eur Heart J Cardiovasc Imaging. 2015;16(11):1198–1206.
   PubMed Web of Science ®Google Scholar
• Tzikas A, Shakir S, Gafoor S, et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER cardiac plug. EuroIntervention. 2016;11(10):1170–1179.
   PubMed Web of Science ®Google Scholar
• Lempereur M, Aminian A, Freixa X, et al. Device-associated thrombus formation after left atrial appendage occlusion: A systematic review of events reported with the Watchman, the Amplatzer Cardiac Plug. and the Amulet. Catheter Cardiovasc Interv. 2017;90(5):E111–E121.
   PubMed Web of Science ®Google Scholar
• Fauchier L, Cinaud A, Brigadeau F, et al. Device-related thrombosis after percutaneous left atrial appendage ccclusion for atrial fibrillation. J Am Coll Cardiol. 2018;71(14):1528–1536.
   PubMed Web of Science ®Google Scholar
• Dukkipati SR, Kar S, Holmes DR Jr., et al. Device-related thrombus after left atrial appendage closure: incidence, predictors, and outcomes. Circulation. 2018;138(9):874–885.
   PubMed Web of Science ®Google Scholar
• Boukobza M, Smaali I, Duval X, et al. Convexity subarachnoid hemorrhage, pseudomonas aeruginosa (PA) infective endocarditis and left atrial appendage occluder (LAAO) device infection. a case report. Open Neuroimag J. 2017;11:26–31.
   PubMedGoogle Scholar
• von Roeder M, Holzhey D, Sandri M, et al. Simultaneous two-sided endocarditis: cardiac resynchronization leads and left atrial appendage occluder. Clin Res Cardiol. 2020. DOI:10.1007/s00392-020-01623-y
   Web of Science ®Google Scholar
• Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009;374(9689):534–542.
   PubMed Web of Science ®Google Scholar
• Holmes DR Jr., Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64(1):1–12.
   PubMed Web of Science ®Google Scholar
• Sondergaard L, Wong YH, Reddy VY, et al. Propensity-matched comparison of oral anticoagulation versus antiplatelet therapy after left atrial appendage closure with WATCHMAN. JACC Cardiovasc Interv. 2019;12(11):1055–1063.
   PubMed Web of Science ®Google Scholar
• Bergmann MW, Betts TR, Sievert H, et al. Safety and efficacy of early anticoagulation drug regimens after WATCHMAN left atrial appendage closure: three-month data from the EWOLUTION prospective, multicentre, monitored international WATCHMAN LAA closure registry. EuroIntervention. 2017;13(7):877–884.
   PubMed Web of Science ®Google Scholar
• Weise FK, Bordignon S, Perrotta L, et al. Short-term dual antiplatelet therapy after interventional left atrial appendage closure with different devices. EuroIntervention. 2018;13(18):e2138–e2146.
   PubMed Web of Science ®Google Scholar
• Jalal Z, Dinet ML, Combes N, et al. Percutaneous left atrial appendage closure followed by single antiplatelet therapy: short- and mid-term outcomes. Arch Cardiovasc Dis. 2017;110(4):242–249.
   PubMed Web of Science ®Google Scholar
• Boersma LV, Ince H, Kische S, et al. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-year follow-up outcome data of the EWOLUTION trial. Heart Rhythm. 2017;14(9):1302–1308.
   PubMed Web of Science ®Google Scholar
• Holmes DR, Reddy VY, Buchbinder M, et al. The assessment of the Watchman device in patients unsuitable for oral anticoagulation (ASAP-TOO) trial. Am Heart J. 2017;189:68–74.
   PubMed Web of Science ®Google Scholar
• Phillips KP, Pokushalov E, Romanov A, et al. Combining Watchman left atrial appendage closure and catheter ablation for atrial fibrillation: multicentre registry results of feasibility and safety during implant and 30 days follow-up. Europace. 2018;20(6):949–955.
   PubMed Web of Science ®Google Scholar
• Wintgens L, Romanov A, Phillips K, et al. Combined atrial fibrillation ablation and left atrial appendage closure: long-term follow-up from a large multicentre registry. Europace. 2018;20(11):1783–1789.
   PubMed Web of Science ®Google Scholar
• Fassini G, Gasperetti A, Italiano G, et al. Cryoballoon pulmonary vein ablation and left atrial appendage closure combined procedure: A long-term follow-up analysis. Heart Rhythm. 2019;16(9):1320–1326.
   PubMed Web of Science ®Google Scholar
• Di Biase L, Burkhardt JD, Mohanty P, et al. Left atrial appendage: an underrecognized trigger site of atrial fibrillation. Circulation. 2010;122(2):109–118.
   PubMed Web of Science ®Google Scholar
• Starck CT, Steffel J, Emmert MY, et al. Epicardial left atrial appendage clip occlusion also provides the electrical isolation of the left atrial appendage. Interact Cardiovasc Thorac Surg. 2012;15(3):416–418.
   PubMed Web of Science ®Google Scholar
• Afzal MR, Kanmanthareddy A, Earnest M, et al. Impact of left atrial appendage exclusion using an epicardial ligation system (LARIAT) on atrial fibrillation burden in patients with cardiac implantable electronic devices. Heart Rhythm. 2015;12(1):52–59.
   PubMed Web of Science ®Google Scholar
• Turagam MK, Lavu M, Afzal MR, et al. Catheter ablation for atrial fibrillation in patients with Watchman left atrial appendage occlusion device: results from a multicenter registry. J Cardiovasc Electrophysiol. 2017;28(2):139–146.
   PubMed Web of Science ®Google Scholar
• Sharma SP, Turagam MK, Gopinathannair R, et al. Direct current cardioversion of atrial fibrillation in patients with left atrial appendage occlusion devices. J Am Coll Cardiol. 2019;74(18):2267–2274.
   PubMed Web of Science ®Google Scholar
• Meier B, Palacios I, Windecker S, et al. Transcatheter left atrial appendage occlusion with Amplatzer devices to obviate anticoagulation in patients with atrial fibrillation. Catheter Cardiovasc Interv. 2003;60(3):417–422.
   PubMed Web of Science ®Google Scholar
• Schmid M, Gloekler S, Saguner AM, et al. Transcatheter left atrial appendage closure in patients with atrial fibrillation. Cardiovasc Med. 2013;16:123–130.
   Google Scholar
• Rodes-Cabau J, Champagne J, Bernier M. Transcatheter closure of the left atrial appendage: initial experience with the Amplatzer Cardiac Plug device. Catheter Cardiovasc Interv. 2010;76(2):186–192.
   PubMed Web of Science ®Google Scholar
• Kleinecke C, Cheikh-Ibrahim M, Schnupp S, et al. Long-term clinical outcomes of Amplatzer Cardiac Plug versus Amulet occluders for left atrial appendage closure. Catheter Cardiovasc Interv. 2019 Oct 21. DOI:10.1002/ccd.28530
   Google Scholar
• Osmancik P, Herman D, Neuzil P, et al. Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation. J Am Coll Cardiol. 2020;75(25):3122–3135.
   PubMed Web of Science ®Google Scholar
• Berti S, Santoro G, Brscic E, et al. Left atrial appendage closure using AMPLATZER devices: A large, multicenter, Italian registry. Int J Cardiol. 2017;248:103–107.
   PubMed Web of Science ®Google Scholar
• Koskinas KC, Shakir S, Fankhauser M, et al. Predictors of early (1-week) outcomes following left atrial appendage closure with Amplatzer devices. JACC Cardiovasc Interv. 2016;9(13):1374–1383.
   PubMed Web of Science ®Google Scholar
• Kleinecke C, Yu J, Neef P et al. Clinical outcomes of Watchman vs. Amplatzer occluders for left atrial appendage closure (WATCH at LAAC). Europace; 10.1093/europace/euaa001 (2020).
   Google Scholar
• Sick PB, Schuler G, Hauptmann KE, et al. Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation. J Am Coll Cardiol. 2007;49(13):1490–1495.
   PubMed Web of Science ®Google Scholar
• Shepal D, Saibal K, Ashish S, et al. Protection against embolism for non-valvular AF subjects: investigational device evaluation of the WATCHMAN FLX™ LAA closure technology: the PINNACLE FLX study. Presentation: Heart Rhythm Socienty Annual Sciencetific Session. (May 8, 2020) Dallas, TX, USA.
   Google Scholar
• Reddy VY, Holmes D, Doshi SK, et al. Safety of percutaneous left atrial appendage closure: results from the Watchman left atrial appendage system for embolic protection in patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation. 2011;123(4):417–424.
   PubMed Web of Science ®Google Scholar
• Reddy VY, Gibson DN, Kar S, et al. Post-approval U.S. experience with left atrial appendage closure for stroke prevention in atrial fibrillation. J Am Coll Cardiol. 2017;69(3):253–261.
   PubMed Web of Science ®Google Scholar
• Reddy VY, Doshi SK, Kar S, et al. 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol. 2017;70(24):2964–2975.
   PubMed Web of Science ®Google Scholar
• Gloekler S, Fürholz M, de Marchi S, et al. Left atrial appendage closure versus medical therapy for atrial fibrillation: the APPLY study. EuroIntervention. 2020. EIJ-D-20-00201. DOI:10.4244/EIJ-D-20-00201.
   Web of Science ®Google Scholar
• Godino C, Melillo F, Bellini B, et al. Percutaneous left atrial appendage closure versus non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation and high bleeding risk. EuroIntervention. 2020;15(17):1548–1554.
   PubMed Web of Science ®Google Scholar
• Reddy VY, Sievert H, Halperin J, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA. 2014;312(19):1988–1998.
   PubMed Web of Science ®Google Scholar
• Meier B, Stegink W, Tzikas A. History of percutaneous left atrial appendage occlusion with AMPLATZER devices. Interv Cardiol Clin. 2018;7(2):151–158.
   PubMedGoogle Scholar
• Kuwata S, Vierecke J, Gloekler S, et al. Left atrial appendage closure for “primary primary” prevention during percutaneous closure of septal defects in patients with large atria but no atrial fibrillation. Cardiol J. 2018;25(2):179–187.
   PubMed Web of Science ®Google Scholar